AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

by Barry101 | Apr 10, 2024 | Press Release

OCALA, Fla., April 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

by Barry101 | Apr 2, 2024 | Press Release

Year marked by growing body of promising data demonstrating Ampligen’s potential to address multiple high-value indications Company to host conference call and webcast today, April 2nd at 8:30 AM ET OCALA, Fla., April 02, 2024 — AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

by Barry101 | Mar 28, 2024 | Press Release

Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

by Barry101 | Mar 26, 2024 | Press Release

OCALA, Fla., March 26, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

by Barry101 | Mar 25, 2024 | Press Release

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis...